¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) Á¦14Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2021 ±¹Á¦Çмú´ëȸ (1ÀÏÂ÷) : 2021-09-02

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) Á¦14Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2021 ±¹Á¦Çмú´ëȸ (1ÀÏÂ÷) : 2021-09-02
±³À°ÀÏÀÚ : 2021-09-02
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À° (½Ç½Ã°£ È­»ó ±³À°)  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) Á¦14Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2021 ±¹Á¦Çмú´ëȸ (1ÀÏÂ÷) 
ÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : °­ÇØÁø
¿¬¶ôó : 02-735-2857  
À̸ÞÀÏ : ksmo3@ksmo.or.kr      
±³À°Á¾·ù : ³»°ú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°úÀÇ·áÁ¤Ã¥
Âü¼®¿¹»óÀοø : 1000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 70,000¿ø      
ºñ°í »çÀüµî·Ï : ȸ¿ø(±³¼ö,Àü¹®ÀÇ,ÀüÀÓÀÇ) -> 5¸¸¿ø ºñȸ¿ø -> 7¸¸¿ø/ ȸ¿ø(Àü°øÀÇ,°£È£»ç,¾à»ç,±ºÀÇ°ü) -> 3¸¸¿ø, ºñȸ¿ø ->5¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀΠ09:00~09:25 Different tumour sequencing strategies in different clinical settings  Lillian L. Siu(Princess Margaret Cancer Centre) 
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀΠ09:25~09:50 Promise and pitfall in tissue-agnostic clinical trial designs??  Vivek Subbiah(The University of Texas MD Anderson Cancer Center) 
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀΠ09:50~10:15 Challenges in clinical decision-making based on sequencing data?  ¹Ú°æÈ­(°í·Á´ëÇб³ ¾È¾Ïº´¿ø) 
Åä·Ð 09-02 ½Ç½Ã°£¿Â¶óÀΠ10:15~10:30 Panel Discussion  -(-) 
È޽Ġ09-02 ½Ç½Ã°£¿Â¶óÀΠ10:30~10:50   () 
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀΠ10:50~11:30 Overcoming resistance to checkpoint blockade immunotherapy  Jedd WOLCHOK(MSKCC) 
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀΠ11:30~12:10 The optimal treatment strategy of mNSCLC patients in the First-line  Shirish Gadgeel(University of Michigan) 
È޽Ġ09-02 ½Ç½Ã°£¿Â¶óÀΠ12:10~12:40   () 
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀΠ12:40~13:05 Analysis of ctDNA  À̽ÂÅÂ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀΠ13:05~13:30 Introduction of ctDNA panels in Korea?  °ø¼±¿µ(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀΠ13:30~13:55 Clinical impact of ctDNA results and perspective  Sarat CHANDARLAPATY(MSKCC) 
Åä·Ð 09-02 ½Ç½Ã°£¿Â¶óÀΠ13:55~14:10 Panel Discussion  -(-) 
È޽Ġ09-02 ½Ç½Ã°£¿Â¶óÀΠ14:10~14:30   () 
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀΠ14:30~14:50 Current status and future perspectives of immunotherapy for gastric cancer  À̱ٿí(ºÐ´ç¼­¿ï´ëÇб³º´¿ø) 
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀΠ14:50~15:10 Evolution of anti-HER2 therapy for gastric cancer  Kohei SHITARA(National Cancer Center Hospital East) 
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀΠ15:10~15:30 Promising new treatments in advanced GIST  ±èÈ¿¼Û(¼¼ºê¶õ½ºº´¿ø) 
È޽Ġ09-02 ½Ç½Ã°£¿Â¶óÀΠ15:30~15:50   () 
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀΠ15:50~16:12 How to select and incooperate adequate biomarkers into clinical trials  Á¤¹Î±Ô(¿¬¼¼¾Ïº´¿ø) 
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀΠ16:12~16:34 How to conduct biomarker driven multi-center clinical trials : networking, logistics, feasibility  Yoshiaki NAKAMURA(National Cancer Center Hospital East) 
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀΠ16:34~16:56 Development of biomarker of IO with clinical trials  ¾È¸íÁÖ(»ï¼º¼­¿ïº´¿ø) 
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀΠ16:56~17:18 Pharmacogenomics for biomarker of toxicities in oncology field  Akinobu HAMADA(National Cancer Center Research Institute) 
Åä·Ð 09-02 ½Ç½Ã°£¿Â¶óÀΠ17:18~17:20 Q&A  () 
±³À°½Ã°£ 09-02 ½Ç½Ã°£¿Â¶óÀΠ17:20~18:00 Sharing experiences and establishment of guidelines of cancer care in COVID-19 pandemic  Giuseppe CURIGLIANO(University of Milano) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) Á¦14Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2021 ±¹Á¦Çмú´ëȸ (1ÀÏÂ÷) : 2021-09-02""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) ´ëÇÑÇǺΰúÇÐȸ ÃæûÁöºÎÇÐȸ : 2021-09-02
´ÙÀ½±Û ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ Á¦ÁÖÁöȸ 9¿ù ¿¬¼ö°­Á : 2021-09-01
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20925 ÀüºÏ Á¦ 53Â÷ ´ëÇѳëÀκ´ÇÐȸ È£³²Áöȸ ÇмúÁý´äȸ : 2024-07-27 0 16 2024-05-28
20924 ¼­¿ï 2024 Á¦27ȸ ´ëÇѾȸ鼺ÇüÀç°ÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-21 0 20 2024-05-28
20923 °æ±â 2024³â ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¾ö : 2024-07-21 0 14 2024-05-28
20922 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(2ÀÏÂ÷) : 2024-07-20 0 8 2024-05-28
20921 ¼­¿ï Á¦33Â÷ ´ç´¢º´ ¿¬±¸ ÇÏ°è¿öÅ©¼¥ : 2024-07-20 0 10 2024-05-28
20920 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GU Cancers 2024 : 2024-07-19 0 15 2024-05-28
20919 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(1ÀÏÂ÷) : 2024-07-19 0 4 2024-05-28
20918 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-07-14 0 5 2024-05-28
20917 °æºÏ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ ¿µ³² ¿¬¼ö°­Á : 2024-07-14 0 5 2024-05-28
20916 °æ±â ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-13 0 7 2024-05-28
20915 °æ±â 2024³â ÀÇÁ¤ºÎÀ»Áö´ëÇб³º´¿ø Á¦1ȸ ½Å°æ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2024-07-13 0 7 2024-05-28
20914 ºÎ»ê Á¦6ȸ ºÎ»ê¼º¸ðº´¿ø ¼Ò¾Æû¼Ò³â°ú ½ÉÆ÷Áö¾ö : 2024-07-13 0 4 2024-05-28
20913 ¼­¿ï 2024 ´ëÇѽŰ泻ºÐºñ¿¬±¸È¸ ¿¬¼ö°­Á : 2024-07-13 0 7 2024-05-28
20912 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦3Â÷¿¬¼ö±³À° : 2024-07-11 0 7 2024-05-28
20911 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-08 0 9 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷